| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Aceneuramic acid targets sialidases (neuraminidases), enzymes that cleave sialic acid residues from glycoproteins and glycolipids. It exhibits inhibitory activity against influenza sialidase type A and type B. As a sialic acid, it is involved in various biological processes, including cell-cell recognition, immune modulation, and pathogen adhesion. Aceneuramic acid is ubiquitous on cell membrane glycoproteins and glycolipids of mammalian cells.
|
|---|---|
| ln Vitro |
In vitro, aceneuramic acid exhibits a range of inhibitory and bioactive properties. It has been tested for inhibition of influenza sialidase type A and type B. As a sialic acid, it is involved in various cellular processes and has been studied for its role in immunomodulation. The compound's bioactivity is related to its function as a terminal monosaccharide on cell surface glycoconjugates.
|
| ln Vivo |
In vivo, aceneuramic acid plays essential roles in mammalian physiology. As the predominant sialic acid in humans, it is involved in cell-cell recognition, immune function, and pathogen interactions. It is a component of gangliosides and glycoproteins that are critical for normal cellular function. Specific in vivo efficacy data for therapeutic applications are limited in publicly available sources.
|
| Enzyme Assay |
In non-cell-based biochemical assays, aceneuramic acid's activity is evaluated using enzyme inhibition assays. Its inhibition of influenza sialidase type A and type B is measured using fluorometric or spectrophotometric methods that detect the cleavage of sialic acid-containing substrates. These assays confirm the compound's activity as a sialidase inhibitor.
|
| Cell Assay |
In vitro cellular assays for aceneuramic acid involve testing its effects on cultured cells. Studies may measure its incorporation into cell surface glycoproteins and glycolipids, its effects on cell signaling, or its ability to inhibit viral attachment and entry. The compound's immunomodulatory properties have been studied in various cellular models.
|
| Animal Protocol |
In vivo animal studies for aceneuramic acid have been conducted in models of viral infection and immune modulation. As a sialidase inhibitor, it has been evaluated for its potential to inhibit influenza virus infection. However, specific protocols and detailed data are limited in publicly available sources. The compound's role as an endogenous metabolite complicates the interpretation of exogenous administration studies.
|
| ADME/Pharmacokinetics |
Aceneuramic acid is an endogenous metabolite that is synthesized and metabolized in the body. It is a component of glycoproteins and glycolipids and is involved in various physiological processes. The compound has a molecular weight of 309.27. As an endogenous compound, its pharmacokinetics are complex and involve synthesis, degradation, and recycling pathways.
|
| Toxicity/Toxicokinetics |
Toxicological data for aceneuramic acid are limited as the compound is an endogenous metabolite. At physiological concentrations, it is well-tolerated. As a research compound, it should be handled with appropriate safety precautions. Its safety profile is consistent with that of other endogenous metabolites used in research applications.
|
| References |
|
| Additional Infomation |
N-acetyl-β-neuraminic acid is an anomeric β-configuration derivative of N-acetylneuraminic acid. It is an epitope. Its function is related to β-neuraminic acid. It is the conjugate acid of N-acetyl-β-neuraminic acid ester.
An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid is found in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (Cited from Dorland, 28th edition, p. 1518) 5-N-acetyl-β-D-neuraminic acid has been reported in Artemia and humans, with relevant data. A mucin subclass containing sialic acid. Aceneuramic acid (N-acetylneuraminic acid, Neu5Ac, sialic acid) is the predominant sialic acid in humans and a critical terminal monosaccharide of glycoproteins and glycolipids. It is a nine-carbon α-keto acid that exhibits inhibitory activity against influenza sialidase type A and type B. Aceneuramic acid is involved in cell-cell recognition, immune modulation, and pathogen interactions. It is also known as lactaminic acid and NANA. |
| Molecular Formula |
C11H21NO9
|
|---|---|
| Molecular Weight |
311.287
|
| Exact Mass |
309.105
|
| CAS # |
131-48-6
|
| Related CAS # |
N-Acetylneuraminic acid-13C;64162-77-2;N-Acetylneuraminic acid-13C-1;1032998-24-5;N-Acetylneuraminic acid-13C-2;220803-19-0;N-Acetylneuraminic acid-13C-3
|
| PubChem CID |
445063
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
762.3±60.0 °C at 760 mmHg
|
| Melting Point |
184-186 °C (dec.)(lit.)
|
| Flash Point |
414.8±32.9 °C
|
| Vapour Pressure |
0.0±5.8 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
-3.98
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
403
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(=O)N[C@@H]1[C@H](C[C@](O[C@H]1[C@@H]([C@@H](CO)O)O)(C(=O)O)O)O
|
| InChi Key |
DXQYQJUKDZLOFX-JKKVJPCISA-N
|
| InChi Code |
InChI=1S/C11H19NO8.H2O/c1-4(10(16)17)19-9-7(12-5(2)14)11(18)20-6(3-13)8(9)15/h4,6-9,11,13,15,18H,3H2,1-2H3,(H,12,14)(H,16,17)1H2/t4-,6?,7+,8-,9-,11+/m1./s1
|
| Chemical Name |
(2R)-2-(((2S,3S,4R,5S)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)oxy)propanoic acid hydrate
|
| Synonyms |
NPC-09 Ace-ER UX-001 Neu-5Ac N-Acetylneuraminic Acid Hydrate Neu5Ac HydrateSA-ER AceERAceneuramic acidNANA Hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~404.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (323.34 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2124 mL | 16.0622 mL | 32.1244 mL | |
| 5 mM | 0.6425 mL | 3.2124 mL | 6.4249 mL | |
| 10 mM | 0.3212 mL | 1.6062 mL | 3.2124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
